In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed

Liu, 2007, Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases, Embo J, 26, 891, 10.1038/sj.emboj.7601545 Besmer, 1993, The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis, Dev Suppl, 125 Broudy, 1997, Stem cell factor and hematopoiesis, Blood, 90, 1345, 10.1182/blood.V90.4.1345 Ogawa, 1991, Expression and function of c-kit in hemopoietic progenitor cells, J Exp Med, 174, 63, 10.1084/jem.174.1.63 Heldin, 2013, Structural and functional properties of platelet-derived growth factor and stem cell factor receptors, Cold Spring Harb Perspect Biol, 5, a009100, 10.1101/cshperspect.a009100 Stanulla, 1995, Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines, Acta Neuropathol, 89, 158, 10.1007/BF00296360 Pittoni, 2011, Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors, Oncogene, 30, 757, 10.1038/onc.2010.494 Kamlah, 2011, Comparison of the effects of carbon ion and photon irradiation on the angiogenic response in human lung adenocarcinoma cells, Int J Radiat Oncol Biol Phys, 80, 1541, 10.1016/j.ijrobp.2011.03.033 Perumal, 2014, Nicotinic acetylcholine receptors induce c-Kit ligand/Stem Cell Factor and promote stemness in an ARRB1/beta-arrestin-1 dependent manner in NSCLC, Oncotarget, 5, 10486, 10.18632/oncotarget.2395 Krasagakis, 2011, KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro, J Cell Physiol, 226, 1099, 10.1002/jcp.22431 Yasuda, 2006, The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells, Mol Cancer, 5, 46, 10.1186/1476-4598-5-46 Yasuda, 2007, Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway, Dig Dis Sci, 52, 2292, 10.1007/s10620-007-9759-7 Gao, 2015, SCF, regulated by HIF-1alpha, promotes pancreatic ductal adenocarcinoma cell progression, PLoS One, 10, e0121338, 10.1371/journal.pone.0121338 Marech, 2014, Possible prognostic and therapeutic significance of c-Kit expression, mast cell count and microvessel density in renal cell carcinoma, Int J Mol Sci, 15, 13060, 10.3390/ijms150713060 Wang, 2014, Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection, Carcinogenesis, 35, 2283, 10.1093/carcin/bgu162 Buchdunger, 2000, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J Pharmacol Exp Ther, 295, 139 Perwein, 2016, Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia, Haematologica, e332, 10.3324/haematol.2015.139568 Qu, 2016, Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in china, Oncotarget Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N Engl J Med, 347, 472, 10.1056/NEJMoa020461 Joensuu, 2015, Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: a prospective study, Radiother Oncol, 116, 233, 10.1016/j.radonc.2015.07.025 Wang, 2000, Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571, Oncogene, 19, 3521, 10.1038/sj.onc.1203698 Krystal, 2001, Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells, Cancer Res, 61, 3660 Carlino, 2014, Resistance to c-Kit inhibitors in melanoma: insights for future therapies, Oncoscience, 1, 423, 10.18632/oncoscience.51 Iqbal, 2014, Imatinib: a breakthrough of targeted therapy in cancer, Chemother Res Pract, 2014, 357027 Ashman, 2013, Therapeutic targeting of c-KIT in cancer, Expert Opin Investig Drugs, 22, 103, 10.1517/13543784.2013.740010 Shui, 1995, Effects of stem cell factor on the growth and radiation survival of tumor cells, Cancer Res, 55, 3431 Maddens, 2002, Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect, Blood, 100, 1294, 10.1182/blood.V100.4.1294.h81602001294_1294_1301 Perez-Losada, 2003, The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor slug, Oncogene, 22, 4205, 10.1038/sj.onc.1206467 Holdhoff, 2005, Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor, Blood Cells Mol Dis, 34, 181, 10.1016/j.bcmd.2004.11.006 Oertel, 2006, Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec), Strahlenther Onkol, 182, 400, 10.1007/s00066-006-1445-8 Ranza, 2009, Influence of imatinib mesylate on radiosensitivity of astrocytoma cells, Anticancer Res, 29, 4575 Qiao, 2013, Imatinib radiosensitizes bladder cancer by targeting homologous recombination, Cancer Res, 73, 1611, 10.1158/0008-5472.CAN-12-1170 Eberle, 2016, Cancer cell motility is affected through 3D cell culturing and SCF/c-Kit pathway but not by X-irradiation, Radiother Oncol, 119, 537, 10.1016/j.radonc.2016.04.036 Franken, 2006, Clonogenic assay of cells in vitro, Nat Protoc, 1, 2315, 10.1038/nprot.2006.339 Storch, 2010, Three-dimensional cell growth confers radioresistance by chromatin density modification, Cancer Res, 70, 3925, 10.1158/0008-5472.CAN-09-3848 Eke, 2009, The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck, PLoS One, 4, e6434, 10.1371/journal.pone.0006434 Na, 2007, [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs, Biochem Pharmacol, 74, 780, 10.1016/j.bcp.2007.05.028 Pietsch, 1998, Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas, Int J Cancer, 75, 171, 10.1002/(SICI)1097-0215(19980119)75:2<171::AID-IJC1>3.0.CO;2-R Mainetti, 2015, Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth, Int J Cancer, 136, 11, 10.1002/ijc.28948 Lennartsson, 2012, Stem cell factor receptor/c-Kit: from basic science to clinical implications, Physiol Rev, 92, 1619, 10.1152/physrev.00046.2011 Zsebo, 1992, Radioprotection of mice by recombinant rat stem cell factor, Proc Natl Acad Sci USA, 89, 9464, 10.1073/pnas.89.20.9464 de Moura, 2013, The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines, Eye (Lond), 27, 92, 10.1038/eye.2012.231 Weigel, 2010, In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells, BMC Cancer, 10, 412, 10.1186/1471-2407-10-412 Yerushalmi, 2007, Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro, Exp Oncol, 29, 126 Phuchareon, 2014, C-kit expression is rate-limiting for stem cell factor-mediated disease progression in adenoid cystic carcinoma of the salivary glands, Transl Oncol, 7, 537, 10.1016/j.tranon.2014.07.006 Salomonsson, 2013, Histological specificity of alterations and expression of KIT and KITLG in non-small cell lung carcinoma, Genes Chromosomes Cancer, 52, 1088, 10.1002/gcc.22103